BioSpace News Archive

Global Cell-Based Assay Market is valued at US$ 19.02 Bn in 2023, and it is expected to reach US$ 35.33 Bn by 2031

With pediatric inflammatory bowel disease diagnoses on the rise globally, a clinical trial in Seattle aims to transform treatment approaches through deep molecular profiling.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced today that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

Akoya Biosciences, Inc., The Spatial Biology Company®, announced its financial results for the first quarter ending March 31, 2024.

Stereotaxis announced that it has entered into a definitive share purchase agreement under which Stereotaxis will acquire Access Point Technologies EP, a privately-held Minnesota-based developer of innovative electrophysiology catheters.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2024.

Cara Therapeutics, Inc., a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced financial results and operational highlights for the first quarter ended March 31, 2024.

Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported additional data on its cell-targeted lipid nanoparticle (ctLNP) platform presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting as well as first quarter 2024 financial results.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended March 31, 2024.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a corporate update.